1043023-98-8

Basic information

• Product Name: C₂₈H₃₂O₅Si
• Synonyms: C₂₈H₃₂O₅Si
• CAS NO: 1043023-98-8
• Molecular Weight: 476.645
• Mol File: 1043023-98-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: C₂₈H₃₂O₅Si(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₈H₃₂O₅Si(1043023-98-8)
• EPA Substance Registry System: C₂₈H₃₂O₅Si(1043023-98-8)

Safety Data

• Hazardous Substances Data: 1043023-98-8(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 56777-24-3 benzyl (S)-Lactate 
• 76271-74-4 2-((t-butyldiphenylsilyl)oxy)acetic acid 

Downstream Products

• 169768-10-9 C₁₂H₁₄O₅ 
• 1192622-33-5 C₂₁H₂₆O₅Si 
• 1192622-34-6 C₃₁H₃₆O₇Si 
• 1239453-58-7 C₂₄H₃₀O₇Si 
• 1192622-35-7 C₁₅H₁₈O₇ 

Relevant articles and documents

Cyclodextrin derivative inclusion compound for treating pancreatic cancer

The invention relates to a cyclodextrin derivative inclusion compound for treating the pancreatic cancer. The existing ways of two active ingredients in the inclusion compound are different, wherein gemcitabine is bonded to a beta-cyclodextrin derivative in a chemical bonding mode first, and then the beta-cyclodextrin derivative further includes erlotinib to form a drug-loaded inclusion compound.Compared with a conventional cyclodextrin inclusion compound, and the beta-cyclodextrin derivative inclusion compound can constantly release the erlotinib and the gemcitabine in the body, so that theerlotinib and the gemcitabine maintain within the effective effect concentration range in the blood for a long time. Therefore, by means of the beta-cyclodextrin derivative inclusion compound, the drug combination curative effect can be obviously improved, and an unexpected excellent effect is generated.